From wiki-pain
Revision as of 09:51, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 2.03
Pain Relevance 0.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C9) oxidoreductase activity (CYP2C9) endoplasmic reticulum (CYP2C9)
CYP2C9 (Homo sapiens)
Pain Link Frequency Relevance Heat
antidepressant 6 99.72 Very High Very High Very High
fluoxetine 11 99.68 Very High Very High Very High
sSRI 56 89.48 High High
cva 2 65.68 Quite High
Antihistamine 1 62.00 Quite High
tricyclic antidepressant 3 60.80 Quite High
Serotonin 11 58.40 Quite High
agonist 3 56.88 Quite High
Triptan 1 55.84 Quite High
Calcium channel 1 49.60 Quite Low
Disease Link Frequency Relevance Heat
Congenital Anomalies 3 94.80 High High
Sprains And Strains 10 91.96 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 35 91.64 High High
Proteinuria 1 81.68 Quite High
Disease 23 80.48 Quite High
Lymphatic System Cancer 51 77.80 Quite High
Sudden Death 1 70.08 Quite High
Vomiting 13 67.24 Quite High
Thrombocytopenia 10 66.60 Quite High
Pulmonary Embolism 1 65.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is not an inhibitor of CYP drug metabolizing enzymes but there is potential for suppression of CYP2C9 and CYP3A at concentrations above 10 ?
Positive_regulation (potential) of Negative_regulation (suppression) of CYP2C9
1) Confidence 0.49 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721288 Disease Relevance 1.41 Pain Relevance 0.03
Tipranavir is metabolized by cytochrome P450 (CYP) 3A and, when combined with ritonavir in vitro, causes inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in addition to induction of glucuronidase and the drug transporter P-glycoprotein.
Positive_regulation (causes) of Negative_regulation (inhibition) of CYP2C9
2) Confidence 0.44 Published 2007 Journal Pharmacotherapy Section Abstract Doc Link 17542771 Disease Relevance 0.24 Pain Relevance 0.14
Etravirine is an inducer of CYP3A4, a weak inhibitor of CYP2C9 and a moderate inhibitor of CYP2C19.
Positive_regulation (inducer) of Negative_regulation (inhibitor) of CYP2C9
3) Confidence 0.23 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2817788 Disease Relevance 0.14 Pain Relevance 0
Some antidepressants are not only substrates for CYP450 metabolism, but are also inhibitors of the metabolic clearance of other drugs, sometimes producing clinically significant drug-drug interactions.32 Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C9, while fluoxetine and paroxetine potently inhibit CYP2D6.
Positive_regulation (substrates) of Negative_regulation (inhibitor) of CYP2C9 associated with antidepressant and fluoxetine
4) Confidence 0.08 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2877605 Disease Relevance 0.24 Pain Relevance 0.54

General Comments

This test has worked.

Personal tools